The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The high activity of Histone deacetylases (HDACs) in hepatocellular carcinoma (HCC) usually positively correlates with poor prognosis of patients.Accordingly histone deacetylases inhibitors (HDACis) are considered to be potential agents treating patients with HCC.In our study, we evaluated effect of quisinostat alone and in combination with sorafenib in HCC cells via inducing G0/G1 phase arrest through PI3K/AKT/p21 pathway and apoptosis by JNK/c-Jun/caspase3 pathway in vitro and in vivo.The proliferation assay and flow cytometry were used to measure the viability, cell cycle and apoptosis.And Western blot assay was carried out to determine expression alternations of related proteins.Moreover HCCLM3 xenograft was further performed to detect antitumor effect of quisinostat in vivo.Here, we found that quisinostat impeded cell proliferation, and remarkably induced G0/G1 phase arrest and apoptosis in HCC cells in a dose-dependent manner.G0/G1 phase arrest was observed by alterations in PI3K/AKT/p21 proteins.Meanwhile the JNK, c-jun and caspase-3 were activated by quisinostat in a dose-dependent manner.Correspondingly quisinostat facilitated G0/G1 cycle arrest and apoptosis in HCC cells through PI3K/AKT/p21 pathways and JNK/c-jun/caspase3 pathways.Moreover, the potent tumor-suppressive effects facilitated by quisinostat, was significantly potentiated by combination with sorafenib in vitro and vivo.The combination treatment of quisinostat and sorafenib markedly suppressed cell proliferation and induced apoptosis in a synergistic manner.Moreover the therapy of quisinostat combined with sorafenib could apparently decrease tumor volume of a HCCLM3 xenograft model.Our study indicated that quisinostat, as a novel chemotherapy for HCC, exhibited excellent antitumor activity in vitro and vivo, which was even enhanced by the addition of sorafenib, implying combination of quisinostat with sorafenib a promising and alternative therapy for patients with advanced hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Consequently it was verified that HDACis shared a multitude of antitumor abilities, especially promoting cell cycle arrest, apoptosis, differentiation and senescence along with altered angiogenesis[30, 31].”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“HDACs overexpression and/or abnormal hyper-activation have been reported to be involved in mostly malignant characters in HCC cells[27, 28].”
BackgroundMann, D. A. (2014) · Hepatology · doi:10.1002/hep.27131 · Cited by 153 · cited 1×
“It was verified that HDAC expression positively correlated with higher incidences of HCC, cell invasion and metastasis and poor prognosis after liver resection[7].”
BackgroundLiu, Y., Zhang, J.-B., Qin, Y., Wang, W., Wei, L., Teng, Y., Guo, L., Zhang, B., Lin, Z., Liu, J., et al. (2013) · Hepatology · doi:10.1002/hep.26398 · Cited by 105
El Fajoui, Z., Toscano, F., Jacquemin, G., Abello, J., Scoazec, J., Micheau, O., & Saurin, J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.055 · Cited by 37
Cited by
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes · doi:10.3390/genes12020260 · Cited by 28
Metadata
- Authors
- He, B., Dai, L., Zhang, X., Chen, D., Wu, J., Feng, X., Zhang, Y., Xie, H., Zhou, L., Wu, J., & Zheng, S.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 14
- Issue
- 13
- Pages
- 1845-1858
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2898344576
- Cited by
- 48
- References
- 8
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.